PeptideClinicLocatorOverview
Selank is a synthetic analog of the immunomodulatory peptide tuftsin. It was developed in Russia and is approved there as an anxiolytic. In the US it is not FDA-approved. Its nomination was withdrawn from the FDA’s Category 2 list in September 2024 (as Selank Acetate/TP-7). That withdrawal does not create a legal compounding pathway—Selank remains unapproved in the US. It has been studied for anxiety, cognitive enhancement, and immune modulation, with clinical studies primarily in Russia. People in the US should not assume it is legally available; evidence and legality are both uncertain stateside.
How It Works (Mechanism of Action)
Selank is thought to modulate anxiety and immune function through effects on neurotransmitters and immune pathways. Russian research has characterized some mechanisms; US data are limited.
Primary Uses
Anxiety, cognitive enhancement, immune modulation. Not FDA-approved in the US. Evidence moderate—clinical studies primarily in Russia.
FDA & Regulatory Status
Not FDA-approved. Nomination withdrawn from Category 2 (September 2024, as Selank Acetate/TP-7). Developed and approved in Russia. No US approval.
Last reviewed February 2026.
Clinical Evidence
Moderate—clinical studies primarily in Russia. Limited US validation.
